United States · Series B startup

Who invested in Pipeline Therapeutics

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$30Mraised across 1 round since 2019, from 1 source

Latest round
Series B, $30MDec 2019
Led by
Sectoral Asset Management
Investors
5 (1 led)
See who backed them

The rounds

  1. Dec 2019

Everyone who backed them

Sectoral Asset ManagementPrivate equity1round, led 1
Versant VenturesVC firm1round
Hadean VenturesPrivate equity1round
RBV CapitalVC firm1round
Cleva Pharma CapitalGrowth equity1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Pipeline Therapeutics

Who invested in Pipeline Therapeutics?

Pipeline Therapeutics's investors include Sectoral Asset Management, Versant Ventures, Hadean Ventures, RBV Capital and Cleva Pharma Capital. Sectoral Asset Management led its latest round.

How much has Pipeline Therapeutics raised?

Pipeline Therapeutics has raised $30M across 1 round since 2019.

When did Pipeline Therapeutics last raise?

Pipeline Therapeutics's most recent round was a Series B of $30M in Dec 2019, led by Sectoral Asset Management.

What was Pipeline Therapeutics's biggest round?

Its most recent round, $30M in Dec 2019, is also its largest on record.

Who backed Pipeline Therapeutics first?

Pipeline Therapeutics's first round on record, in Dec 2019, was backed by Sectoral Asset Management, Versant Ventures and Hadean Ventures and 2 others.

What stage is Pipeline Therapeutics at?

Pipeline Therapeutics's latest named round is a Series B, in Dec 2019.

Where is Pipeline Therapeutics based?

Pipeline Therapeutics is based in the United States.

Who led Pipeline Therapeutics's rounds?

Sectoral Asset Management led the Series B in 2019.

Companies like Pipeline Therapeutics

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.